A new drug developed by Taipei-based Foresee Pharmaceuticals Co. to treat acute respiratory distress syndrome (ARDS) in COVID-19 patients has received the approval of an independent data monitoring committee (IDMC) in the United States.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Taiwan headline news
09/09/2026 10:17 AM - Business
U.S. dollar down in Taipei trading
09/09/2026 10:13 AM - Business
Taiwan shares open higher
09/09/2026 09:14 AM - Politics
Bloc Québécois leader backs Taiwan's global role, stronger ties
09/08/2026 09:18 PM - Sports
Taiwan routs Thailand 18-0 in U18 Asian Baseball Championship
09/08/2026 09:07 PM